Skip to main content

Detail

Alexandra Kautzky-Willer
Univ.-Prof. Dr. Alexandra Kautzky-WillerHead of the Gender Medicine Unit and the University Course Gender Medicine. Deputy head of the Department of Internal Medicine III. President of the Austrian Society of Gender-Specific Medicine

Department of Medicine III (Division of Endocrinology and Metabolism)
Position: Professor

ORCID: 0000-0002-3520-4105
T +43 1 40400 22280
alexandra.kautzky-willer@meduniwien.ac.at

Further Information

Keywords

-gender differences; Diabetes Mellitus; Metabolic Syndrome X; Obesity; Sex

Research group(s)

Research interests

  • Endocrinology
  • Gestational diabetes and fetal programming
  • Gender aspects of obesity
  • Gender aspects of metabolic syndrome
  • Gender aspects of type 2 diabetes
  • Gender aspects of type 1 diabetes/autoimmunity
  • Gender aspects of insulin resistance and beta cell function: Changes in pathogenesis of and interaction with different disease processes
  • Gender aspects of inflammation, adipokines, endothelial dysfunction

Techniques, methods & infrastructure

- Functional tests, insulin sensitivity, insulin secretion, incretins;
- Glucose monitoring
- Minimal modeling
- Spectroscopy

Grants

  • Optimal gender-specific treatment paths on healthcare multiplex networks (2017)
    Source of Funding: WWTF (Vienna Science and Technology Fund), Mathematics and…
    Principal Investigator
  • Epigenetik-basierte Typ-2-Diabetes Diagnostik aus Speichel und Blut (2015)
    Source of Funding: FFG (Austrian Research Promotion Agency), FEMtech
    Principal Investigator
  • DIABgender: Gender-specific Diabetes Self-management (2014)
    Source of Funding: FFG (Austrian Research Promotion Agency), FEMtech FTI
    Principal Investigator
  • DALI: Vitamin D and lifestyle intervention for gestational diabetes mellitus (GDM) prevention (2010)
    Source of Funding: EU, FP7
    Principal Investigator

Selected publications

  1. Kautzky-Willer, A. & Harreiter, J., 2017. Sex and gender differences in therapy of type 2 diabetes. Diabetes Research and Clinical Practice, 131, pp.230-241. Available at: http://dx.doi.org/10.1016/j.diabres.2017.07.012.
  2. Kautzky-Willer, A., Harreiter, J. & Pacini, G., 2016. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocrine Reviews, 37(3), pp.278-316. Available at: http://dx.doi.org/10.1210/er.2015-1137.
  3. Kautzky-Willer, A., Thurner, S. & Klimek, P., 2016. Use of statins offsets insulin-related cancer risk. Journal of Internal Medicine, 281(2), pp.206-216. Available at: http://dx.doi.org/10.1111/joim.12567.
  4. Harreiter, J. et al., 2016. IADPSG and WHO 2013 Gestational Diabetes Mellitus Criteria Identify Obese Women With Marked Insulin Resistance in Early Pregnancy: Table 1. Diabetes Care, 39(7), pp.e90-e92. Available at: http://dx.doi.org/10.2337/dc16-0200.
  5. Owens, D.R. et al., 2017. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100�U/mL added to oral antidiabetes agents in type 2 diabetes. Diabetes, Obesity and Metabolism. Available at: http://dx.doi.org/10.1111/dom.12966.